Vaccines are also slated to be approved for children in the coming months and this could also be a near-term driver of sales. With vaccinations happening at a rate of about 30 million doses per day globally, and two doses required for most shots, there’s probably some more room to drive volumes for vaccine majors. That’s enough doses to vaccinate about 44% of the global population. More than 6.73 billion Covid-19 vaccine doses have been administered thus far worldwide, per the Bloomberg Vaccine Tracker. However, are vaccine stocks still worth a look for investors at this point? The rally was largely warranted, given the urgency to contain the pandemic, the speed with which most players produced and distributed vaccines, and the stellar financial results that for-profit players such as Moderna (NASDAQ: MRNA) have posted in recent quarters. Our theme of Covid-19 Vaccine Stocks has outperformed meaningfully since then, rising by about 115% over the last twelve months, compared to a return of just about 32% on the S&P 500 over the same period. It’s been almost a year since Pfizer (NYSE:PFE) published incredibly strong efficacy data from its phase 3 Covid-19 vaccine trials, setting the stage for one of the largest inoculation drives in history.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |